In the present and future of the Greek pharmaceutical industry and its contribution to the economy and the NHS, the Minister of Health Adonis Georgiadis, the President of the Panhellenic Union of Pharmaceuticals (PEF) Theodoros Tryfas, the Vice President Emergency readiness and treatment in Hera, in a discussion at the Economist conference entitled “29th Annual Government Roundtable – Walking Steadily Across a Tightrope of Uncerty”.

“Greece a small superpower in the production of drugs”

Greece can become a hub of drugs and in this direction there have been significant steps, Mr Georgiadis said.

“Apart from the millions of sheep produced by Greece, but it really produces medicines and in this area Greece, for its size, is a small superpower,” the minister said.

About 12% of the consumption of drugs in the EU are produced in a Greek factory.

He noted that this government with actions rather than words, with specific policies, has made a decisive contribution to the present, but mainly to the future of the Greek pharmaceutical industry.

The subcontinent referred to the ongoing investments currently in the Greek pharmaceutical industry, but also by multinational companies, through the investment clawback and the incentives given. Investments reach 1.6 billion euros, the minister said, and announced that there would be new investments, allowing us to have solid foundations in production.

The evolution of the indicative clawback has already been announced for the next three years with additional funding from the state budget, he added.

Speaking about pharmaceutical policy, the minister said the application is planned to the electronic prescription, a filter that combines the SPC of the drugs with the ICD 10 to filter if one drug is in contrast to another taken. The annual savings of its implementation may exceed € 400 million.

As he said, the measure will be implemented in 2025 to “achieve a meaningful savings so that, together with the additional funding we have secured and the introduction of the Innovation Fund, to build a sustainable environment for the coming years in Greece, which can welcome the new innovative treatments”.

For his part, the President of the Panhellenic Union of Pharmaceuticals (PEF) Theodoros Tryfon, spoke of an unstable environment internationally, saying: “For the first time we have a pending environment where Europe has to start rewriting a narrative and in terms of security and security and in terms of its new and security model.

We have to put some European and some national constants. Greece has a large investment gap and despite the positive steps, the investment gap reaches 12 to 15 billion a year. At the same time it has great dependence on services, so much less industry and production in GDP. “If they are not resolved we will come back to a memorandum again,” Mr Tryphon said.

He added that public money should be directed to development sectors and, referring to the Greek pharmaceutical industry, noted that it is in the three sectors that used the 300 million it received with enormous added value.

He also spoke of more incentives for Greek and foreign pharmaceutical companies to invest in Greece.